At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Giampaolo Bianchini, MD, of the San Raffaele Scientific Institute, Milan, Italy, explains the evidence requirements for the clinical development of prognostic and predictive genomic tests for individual risk stratification and adjuvant treatment selection in breast cancer patients.
European Medical Journal
Website: http://emjreviews.com/
Twitter: https://twitter.com/EMJReviews
Facebook: https://www.facebook.com/emjreviews
Advertisement Single Between Content
Advertisement Single Between Content
Advertisement Single Between Content
This content is supported by Genomic Health, Inc.
Advertisement Single Below Content
Advertisement Single Below Content
Advertisement Single Below Content